{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.9","upperLimit":"6.5","value":"2.91"}]}],"title":"Time to First Response"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.9","upperLimit":"7.5","value":"3.45"}]}],"title":"Time to Best Response"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.9","upperLimit":"7.5","value":"3.02"}]}],"title":"Time to Complete Response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"87"}],"units":"Participants"}],"description":"Time to first response was defined as time in months from the date of first treatment to the first date when any response is achieved. Time to best response was defined in months from the date of first treatment to the first date when a subject's best response, in the order of CR, CRi (or CRp or CRh), or PR, was achieved. Time to CR was defined in months from the date of first treatment to the first date when CR is achieved. CR:ANC ≥1000/ microliter (μL),platelets ≥100,000/μL,independence from RBC and platelet transfusions over the past week, no leukemic blasts, and \\<5% leukemic blasts.CRp: CR criteria except ANC ≥1000/μL, platelets \\< 100,000/μL.and platelet transfusion over the past week. CRi:CR criteria except ANC \\<1000/μL or platelets \\<100,000/μL.CRh: \\<5% of blasts in the bone marrow,platelets \\>50,000/μL and ANC \\>500/μL, independence from RBC and platelet transfusions within 7 days and peripheral blast ≤1%. PR: CR criteria except decrease of ≥50% in leukemic blasts.","dispersionType":"Full Range","groups":[{"description":"Participants with AML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycle 1 (each cycle = 28 days), followed by IV infusion of decitabine 20 mg/m\\^2, once daily, on Days 1 to 5 in cycle 2 or the converse. A washout period of 23 days was maintained between the 2 cycles. From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.","id":"OG000","title":"AML: ASTX727 or IV Decitabine"}],"paramType":"MEDIAN","populationDescription":"Efficacy Analysis Set included all participants who received any amount of study treatment.","reportingStatus":"POSTED","timeFrame":"Up to approximately 2.4 years","title":"AML: Time to First Response, Best Response and Complete Response Based on IWG 2003 AML Response Criteria","type":"SECONDARY","unitOfMeasure":"months"}